Welcome to our dedicated page for Soleno Therapeutics news (Ticker: SLNO), a resource for investors and traders seeking the latest updates and insights on Soleno Therapeutics stock.
Soleno Therapeutics Inc (SLNO) is a clinical-stage biopharmaceutical company pioneering treatments for rare diseases, with a focus on Prader-Willi Syndrome (PWS). This page provides investors and healthcare professionals with authoritative updates on the company’s lead candidate DCCR, regulatory progress, and strategic initiatives.
Access timely press releases and curated news about clinical trial developments, FDA designations, and research breakthroughs. Our coverage spans key areas including Phase 3 trial updates, patent filings, and partnership announcements related to metabolic disorder therapeutics.
Bookmark this page for structured access to Soleno’s latest scientific advancements and corporate communications. Check regularly for verified information about DCCR’s extended-release formulation and its potential impact on PWS management.
Soleno Therapeutics announced the publication of a comparison study showing significant improvements in hyperphagia and PWS-related behaviors with DCCR treatment for Prader-Willi syndrome. The study demonstrated positive results from the Phase 3 trials, indicating the potential of DCCR to enhance the quality of life for PWS patients.
Soleno Therapeutics has received Breakthrough Therapy Designation from the U.S. FDA for DCCR in Prader-Willi Syndrome (PWS), marking the first ever for a drug developed for PWS. The designation is based on Phase 3 data, with plans for an NDA submission in mid-2024.
FAQ
What is the current stock price of Soleno Therapeutics (SLNO)?
What is the market cap of Soleno Therapeutics (SLNO)?
